SGLT 2 inhibitors provide kidney, cardiovascular benefits for diabetes patients

Published On 2021-11-13 09:29 GMT   |   Update On 2021-11-13 09:29 GMT

In addition to lowering blood sugar levels, diabetes drugs called Sodium-glucose cotransporter 2 (SGLT2) inhibitors can provide kidney- and cardiovascular-related benefits for people with type 2 diabetes.

A recent study has found that such benefits are also experienced by individuals with type 1 diabetes. There is a significant risk reductions for cardiovascular disease and kidney failure with SGLT2 inhibitor treatment in type 1 diabetes, confirms study.

For more details, check out the full story on the link

SGLT2 Inhibitors May Protect Kidney And Heart In Adults With Type 1 Diabetes: Study

Full View
Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News